Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 1151802 trials

Qurient Co., Ltd.

Official website

KOSDAQ biotech spun off from Institut Pasteur Korea, developing oncology and antibiotic drugs plus a drug distribution business.

As of 2026-10-10, Qurient Co., Ltd. has 14 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2008 and listed on KOSDAQ in 2016, Qurient Co., Ltd. is a drug development biotech spun off from the Institut Pasteur Korea to commercialize its research outcomes. Its pipeline includes the CDK7 inhibitor mocaciclib (Q901), the Axl/Mer/CSF1R triple inhibitor adrixetinib (Q702), the next-generation dual-payload ADC QP101, the antibiotic telacebec (Q203), and the atopic dermatitis drug Q301, alongside a prescription drug distribution business. The company is organized into an R&D division and a drug distribution division, co-develops Keytruda combination regimens with MSD, out-licensed telacebec to the TB Alliance in February 2023, and reported consolidated revenue of KRW 7.0 billion at end-2025 and KRW 9.1 billion at end-2024.

Products & technology

  • Pharmaceutical distribution businessSale of prescription and over-the-counter drugs

Clinical trials

data.go.kr

2 MFDS clinical trial authorisations · 2022–2023 (Phase 1/2 2)

  • Phase 1/2Q901, 키트루다주2023-06-21

    14 trial sites

  • Phase 1/2Q702, 키트루다주2022-09-06

    10 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

Mocaciclib(Q901) · 난소암, 전립선암, 유방암, 자궁내막암, 결장직장암, 소세포폐암 또는 췌장암 · 1/2상 진행중(단독/병용) · CDK7 inhibitor in Phase 1/2 (monotherapy/combination) trials in the US and Korea; co-developed with MSD as a Keytruda combination and used as the basis for the QP101 ADC

QP101 · 고형암 · 비임상(단독) · Next-generation dual-payload ADC based on a topoisomerase 1 inhibitor, in preclinical stage

Adrixetinib(Q702) - 진행형 고형암 · 진행형 고형암 · 1상 완료(단독), 미국 · Axl/Mer/CSF1R triple inhibitor

Adrixetinib(Q702) - 이식편대숙주질환/희귀혈액암 · 만성 이식편대숙주질환, 희귀 혈액암 · 1상 진행중(단독), 미국 · Axl/Mer/CSF1R triple inhibitor

Adrixetinib(Q702) - 병용 고형암 · 위암, 식도암, 간암, 자궁경부암 · 1B/2상 진행중(병용), 미국·한국 · Developed as a Keytruda combination under a co-development agreement with MSD

Adrixetinib(Q702) - 급성 골수성 백혈병 · 급성 골수성 백혈병 · 1상 진행중(단독), 미국 · Axl/Mer/CSF1R triple inhibitor

Telacebec(Q203) · 다제내성결핵, 부룰리 궤양, 한센병 · 2/3상 진행중(단독), 미국·호주·남아공 · Cytochrome bc1 inhibitor; out-licensed to the TB Alliance in February 2023, began a registrational trial in Australia for Buruli ulcer in July 2024, dosing about 40 patients in 2024 and 100 in 2025; expected to be Qurient's first approved drug once the expanded trial completes

Q301 · 아토피성피부염 · 2B상 완료(단독), 미국 · Topical 5-LO inhibitor; various commercialization strategies under discussion based on Phase 2 efficacy results

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 4 more publications

Patents

KIPRIS · applicant-matched
Show 79 more patents

AI reads

MAA server logs · IP-verified
69
Times AI engines pulled Qurient Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

0
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

69
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 0
Last 7 days
55
live 0
Last 30 days
69
live 0
All time
  • OpenAIOAI-SearchBot64
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Qurient Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition